Adverse Events Associated with Devices for Incisional Glaucoma Surgery Performed with Implants as Reported to the FDA MAUDE Database.

IF 2.4 3区 医学 Q2 OPHTHALMOLOGY
Kaylie Chen, Pooja Pendri, Kyle Kovacs, Sarah H Van Tassel
{"title":"Adverse Events Associated with Devices for Incisional Glaucoma Surgery Performed with Implants as Reported to the FDA MAUDE Database.","authors":"Kaylie Chen, Pooja Pendri, Kyle Kovacs, Sarah H Van Tassel","doi":"10.1007/s00417-025-06771-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Incisional glaucoma surgery is indicated in advanced glaucoma or glaucoma refractory to less invasive therapies, and can be performed with implants to lower IOP including glaucoma drainage or filtration devices. The Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) represents the largest U.S. publicly-available repository of device-related incisional glaucoma surgery complications, enabling insight into complications experienced with incisional glaucoma surgery in real-world practice to develop a risk profile for the use of each device.</p><p><strong>Methods: </strong>MAUDE database was searched between January-2012 and December-2021 for Brand Name: Ahmed ClearPath, Ahmed Glaucoma Valve, Baerveldt, Ex-PRESS, and Molteno. Reports were categorized by complication;when multiple were present, multiple categories were attributed. Reports with identical text and dates were counted as duplicate and excluded. Literature reports comparing multiple devices without clear device specification per complication were excluded.</p><p><strong>Results: </strong>The search yielded 1538 reports, of which 1379 reports describing 2429 adverse events met inclusion criteria. The most common events for were hypotony/hypotony maculopathy (284), device-iris touch (282), device occlusion (213), elevated IOP (210), and device explanted due to possible exclusion (176). Delivery system failures occurred (166). Patients also experienced flat/shallow anterior chambers (147) and corneal edema/bullous keratopathy/endothelial cell count reduction/corneal decompensation/Descemet's membrane tears (128).</p><p><strong>Conclusion: </strong>By drawing on the real-world complications collected in the MAUDE database, this study identifies adverse events of greatest clinical pertinence for device-related incisional glaucoma surgery overall and by brand. Understanding the most common adverse events may support surgeons in counseling patients and preparing for device implantation.</p>","PeriodicalId":12795,"journal":{"name":"Graefe’s Archive for Clinical and Experimental Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Graefe’s Archive for Clinical and Experimental Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00417-025-06771-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Incisional glaucoma surgery is indicated in advanced glaucoma or glaucoma refractory to less invasive therapies, and can be performed with implants to lower IOP including glaucoma drainage or filtration devices. The Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) represents the largest U.S. publicly-available repository of device-related incisional glaucoma surgery complications, enabling insight into complications experienced with incisional glaucoma surgery in real-world practice to develop a risk profile for the use of each device.

Methods: MAUDE database was searched between January-2012 and December-2021 for Brand Name: Ahmed ClearPath, Ahmed Glaucoma Valve, Baerveldt, Ex-PRESS, and Molteno. Reports were categorized by complication;when multiple were present, multiple categories were attributed. Reports with identical text and dates were counted as duplicate and excluded. Literature reports comparing multiple devices without clear device specification per complication were excluded.

Results: The search yielded 1538 reports, of which 1379 reports describing 2429 adverse events met inclusion criteria. The most common events for were hypotony/hypotony maculopathy (284), device-iris touch (282), device occlusion (213), elevated IOP (210), and device explanted due to possible exclusion (176). Delivery system failures occurred (166). Patients also experienced flat/shallow anterior chambers (147) and corneal edema/bullous keratopathy/endothelial cell count reduction/corneal decompensation/Descemet's membrane tears (128).

Conclusion: By drawing on the real-world complications collected in the MAUDE database, this study identifies adverse events of greatest clinical pertinence for device-related incisional glaucoma surgery overall and by brand. Understanding the most common adverse events may support surgeons in counseling patients and preparing for device implantation.

FDA MAUDE数据库报告的切口青光眼植入手术器械相关不良事件
目的:切口青光眼手术适用于晚期青光眼或微创治疗难治性青光眼,可采用植入物降低IOP,包括青光眼引流或滤过装置。美国食品和药物管理局(FDA)制造商和用户设施设备体验(MAUDE)代表了美国最大的与设备相关的切口青光眼手术并发症的公开存储库,使人们能够深入了解现实世界中切口青光眼手术的并发症,从而为使用每种设备制定风险概况。方法:在MAUDE数据库中检索2012年1月至2021年12月的品牌名称:Ahmed ClearPath、Ahmed Glaucoma Valve、Baerveldt、Ex-PRESS和Molteno。报告按并发症分类;当出现多个时,多个类别被归为。具有相同文本和日期的报告被视为重复并被排除。没有明确器械规格的多个器械比较的文献报告被排除。结果:检索得到1538份报告,其中1379份报告描述了2429个不良事件符合纳入标准。最常见的事件是低眼压/低眼压黄斑病变(284),器械-虹膜接触(282),器械闭塞(213),IOP升高(210),以及由于可能排除的器械外植(176)。交付系统发生故障(166)。患者还会出现扁平/浅前房(147)和角膜水肿/大疱性角膜病变/内皮细胞计数减少/角膜失代偿/Descemet膜撕裂(128)。结论:通过利用MAUDE数据库中收集的真实世界并发症,本研究确定了器械相关切口青光眼手术总体上和品牌上最具临床针对性的不良事件。了解最常见的不良事件可以帮助外科医生为患者提供咨询并为植入器械做准备。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.40
自引率
7.40%
发文量
398
审稿时长
3 months
期刊介绍: Graefe''s Archive for Clinical and Experimental Ophthalmology is a distinguished international journal that presents original clinical reports and clini-cally relevant experimental studies. Founded in 1854 by Albrecht von Graefe to serve as a source of useful clinical information and a stimulus for discussion, the journal has published articles by leading ophthalmologists and vision research scientists for more than a century. With peer review by an international Editorial Board and prompt English-language publication, Graefe''s Archive provides rapid dissemination of clinical and clinically related experimental information.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信